Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFM11
- Development stage
- Discontinued
- Lead developer
- Affimed
- Modality
- Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AFM11 is a bispecific, tetravalent humanized recombinant antibody construct (TandAb) developed by Affimed Therapeutics for the treatment of hematologic malignancies, specifically relapsed or refractory non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)[1][4][6]. It is designed to bind simultaneously to CD19 on B-cells and CD3 on T-cells. By bridging these two cell types, AFM11 recruits and activates T-cells to induce cytotoxicity against malignant B-cells through antibody-dependent cell-mediated cytotoxicity. The drug does not directly kill cancer cells but stimulates the immune system’s T-cell response to target and destroy CD19-positive cancer cells[4][5][7]. Clinical development was discontinued after phase 1 trials due to safety concerns including severe neurological adverse events[1][6].
- Other names
- anti-CD19/CD3 tetravalent antibody AFM11
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on AFM11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFM11.